

Human Afamin Alexa Fluor® 532-conjugated Antibody

Antigen Affinity-purified Polyclonal Sheep IgG Catalog Number: AF8065X

100 µg

DESCRIPTION	
Species Reactivity	Human
Specificity	Detects human Afamin in direct ELISAs and Western blots. In direct ELISAs, approximately 40% cross-reactivity with recombinant mouse Afamin is observed, and less than 1% cross-reactivity with recombinant human (rh) AFB and rhAFP is observed.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	Human embryonic kidney cell line HEK293-derived recombinant human Afamin Leu22-Asn599 Accession # P43652
Conjugate	Alexa Fluor 532 Excitation Wavelength: 534 nm Emission Wavelength: 553 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
	*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

AFM (Afamin; also α-Albumin) is a secreted monomeric glycoprotein member of the Alb/albumin family of molecules. Although its MW in SDS-Page ranges from 84-88 kDa, MALDI-TOF analysis yields a likely more correct value of 70-75 kDa. It is expressed by hepatocytes, CNS endothelial cells and osteoclasts, and circulates in the blood at low μg/mL concentrations. AFM is known to bind and transport vitamin E, particularly under conditions where lipoprotein is limited. This is likely to be important in follicular fluid and CSF. It also serves as an osteoclast-derived chemoattractant for preosteoblasts, providing a rational for the observation that bone formation often follows bone resorption. Mature human AFM is 578 amino acids (aa) in length (aa 22-599). It contains three consecutive albumin domains (aa 36-206, 211-403 and 404-599) that contain a characteristic 5 or 6 intrachain disulfide bonds. Full-length human AFM shares 67% aa sequence identity with mouse AFM.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Rev. 9/17/2025 Page 1 of 1